Growing Through Challenges? – iBio Inc (IBIO)

Currently, there are 3.48M common shares owned by the public and among those 3.47M shares have been available to trade.

The company’s stock has a 5-day price change of 275.93% and 185.92% over the past three months. IBIO shares are trading 196.35% year to date (YTD), with the 12-month market performance down to -91.29% lower. It has a 12-month low price of $1.02 and touched a high of $49.80 over the same period. IBIO has an average intraday trading volume of 2.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 222.54%, 239.54%, and -24.77% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of iBio Inc (AMEX: IBIO) shares accounts for 7.22% of the company’s 3.48M shares outstanding.

It has a market capitalization of $14.13M and a beta (3y monthly) value of -3.61. The earnings-per-share (ttm) stands at -$26.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 24.27% over the week and 9.55% over the month.

Analysts forecast that iBio Inc (IBIO) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2025. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$2.05 a year ago.

Looking at the support for the IBIO, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on November 29, 2021, with the firm’s price target at $1.50. Cantor Fitzgerald coverage for the iBio Inc (IBIO) stock in a research note released on January 22, 2021 offered a Overweight rating with a price target of $3.

Most Popular

Related Posts